Prognostic Value of Drinking Status and Aldehyde Dehydrogenase 2 Polymorphism in Patients With Head and Neck Squamous Cell Carcinoma

DOI Web Site PubMed 8 Citations Open Access
  • Kawakita Daisuke
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences
  • Oze Isao
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute
  • Hosono Satoyo
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute
  • Ito Hidemi
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute
  • Watanabe Miki
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute
  • Yatabe Yasushi
    Department of Pathology and Molecular Diagnosis, Aichi Cancer Center Hospital
  • Hasegawa Yasuhisa
    Department of Head and Neck Surgery, Aichi Cancer Center Hospital
  • Murakami Shingo
    Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences
  • Tanaka Hideo
    Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute Department of Epidemiology, Nagoya University Graduate School of Medicine
  • Matsuo Keitaro
    Department of Epidemiology, Nagoya University Graduate School of Medicine Division of Molecular Medicine, Aichi Cancer Center Research Institute

Search this article

Abstract

Background: The association between alcohol drinking, aldehyde dehydrogenase 2 (ALDH2) polymorphism, and survival in patients with head and neck squamous cell carcinoma (HNSCC) remains unclear.<BR>Methods: We performed a retrospective cohort study of 267 HNSCC patients at Aichi Cancer Center. Of these, 65 patients (24%) were non-drinkers, 104 (39%) were light drinkers (ethanol <46 g or <5 days/week), 46 (17%) were moderate drinkers (ethanol intake 46–68 g/day and ≥5 days/week), and 52 (20%) were heavy drinkers (ethanol intake ≥69 g and ≥5 days/week). The prognostic value of pre-treatment drinking status and ALDH2 polymorphism was investigated using multivariate proportional hazard models.<BR>Results: Drinking status was associated with disease-free survival (DFS) in HNSCC patients, with marginal statistical significance (5-year DFS: 67.9% [95% confidence interval {CI}, 53.8–78.4%] for non-drinkers, 57.6% [95% CI, 47.4–66.6%] for light drinkers, 46.1% [95% CI, 30.8–60.1%] for moderate drinkers, and 43.5% [95% CI, 29.3–56.9%] for heavy drinkers; P = 0.088). However, this association lost significance when multivariate analyses were adjusted for established prognostic factors. ALDH2 genotype was not significantly associated with DFS in HNSCC patients (5-year DFS: 85.7% [95% CI, 53.9–96.2%] for Lys/Lys, 56.2% [95% CI, 47.4–64.1%] for Glu/Lys, and 50.5% [95% CI, 40.3–59.7%] for Glu/Glu; P = 0.154). After stratification by ALDH2 genotype, we observed a significant positive dose-response relationship between drinking status and DFS in HNSCC patients with ALDH2 Glu/Glu (Ptrend = 0.029).<BR>Conclusions: In this study, we identified a significant positive dose-response relationship between pre-treatment drinking status and DFS in HNSCC patients with ALDH2 Glu/Glu. To confirm this association, further study is warranted.

Journal

Citations (8)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top